Stefan Sandström, författare på Biosector Ltd.

Stefan speaking on stage at a pharmaceutical industry conference, in front of a large presentation screen about Daiichi Sankyo, antibody-drug conjugates, and new business opportunities in oncology.

by Stefan Sandström

August 10, 2026

Daiichi Sankyo ADC strategy: Where Your New Opportunities Lie

Daiichi Sankyo has built one of the pharmaceutical industry’s most productive antibody-drug conjugate platforms. Enhertu has […]

0

A photorealistic illuminated billboard beside a wet city road at dusk, displaying: "Otsuka's new target is to hit ¥3.5 trillion by 2035."

by Stefan Sandström

New Ambitious Goals and Strategies for Otsuka: Where Your New Opportunities Are

Large pharmaceutical targets often look like abstract financial noise to external vendors. But Otsuka’s target to […]

0

A man in a dark suit stands and points at a large projection screen with Japanese text and "LIFE SCIENCES LAB" graphics, inside a high-rise office overlooking the Tokyo skyline and Tokyo Tower. A seated audience, including people in lab coats, listens.

by Stefan Sandström

Japan Market Entry for Life Science Companies | Biosector

This article: Japan market entry can produce meetings, contacts and polite interest without producing commercial traction. […]

0

A high-angle photograph shows several people's hands working together to assemble a large, cardboard jigsaw puzzle on a light-colored wooden table surface. The central hub of the puzzle is a circular piece clearly labeled with "Tanabe Pharma". Other interlocking pieces are being added around it. One large piece on the upper right is labeled "Shionogi", and connected to it is a piece labeled "Radicava". On the lower left, a piece is labeled "Towa Pharma", and it is connected to a smaller, specific piece labeled "17 legacy drugs", which also connects back to the Tanabe hub. Other blank, unassembled puzzle pieces are scattered around the main assembly area, and blurred window frames are visible in the background. At least four or five separate hands are visible, representing different individuals or entities, suggesting multi-party cooperation or negotiation. The lighting is soft and even, highlighting the textures of the hands and the cardboard pieces.

by Stefan Sandström

The Tanabe Carve-Out: A Masterclass in Japan Pharma Market Strategy

Japan’s pharmaceutical ecosystem is seemingly undergoing a profound structural shift. If you are targeting the Japanese […]

0

A conceptual illustration of an hourglass with a human brain at the top, releasing a cascade of binary code (1s and 0s) and data symbols. At the bottom red bulb, two robotic hands are analyzing and sorting this data into categories marked by red checkmarks and black cross-marks. A factory and cherry blossoms are in the background.

by Stefan Sandström

Beyond the $2.1B Hype: Why Biology Remains the Kingmaker

The biopharma world is still processing the seismic news of Isomorphic Labs’ $2.1 billion Series B […]

0

by Stefan Sandström

Japan Drug Pricing and the New Global Price Pressure

Japan’s pharmaceutical pricing system is often seen as a local matter. It is discussed in terms […]

0

Editorial illustration showing drug discovery evolving from primitive narrow target panels, through patient risk, toward modern mass spectrometry based off-target profiling and healthier treatment outcomes.

by Stefan Sandström

Modern Off-Target Profiling: The Murderous Reality Behind Clean Safety Panels

The Easy Hurdle That Kills Programs A drug candidate can clear the standard off-target panel and […]

0

Wide illustration showing Japan as an interconnected medical device market entry ecosystem, with nodes for PMDA and MHLW regulation, hospitals, reimbursement, distributors, manufacturing, digital health, and overseas investors.

by Stefan Sandström

Japan Medical Device Market Entry Strategy

Japan is no longer a market foreign medical device companies can afford to treat as “difficult […]

0

Editorial business illustration showing a giant wasp approaching a Takeda executive in a boardroom as dominoes labeled patent cliff, revenue erosion, cost savings, and workforce reduction begin to fall.

by Stefan Sandström

Takeda is Living the Japanese Proverb: “Wasp stings a crying eye”

The High Stakes of Innovation: Balancing Takeda’s $1.26B ‘Launch Machine’ and a $2.5B Antitrust Hit as […]

0

Illustration showing the global impact of Most Favoured Nation drug pricing policies, featuring the US Capitol, Japan, pharmaceutical pricing scales, global market connections, and declining pricing graphs symbolizing pressure on global pharma economics and innovation.

by Stefan Sandström

America Wants Cheaper Drugs. Japan May End Up Paying the Price.

The global pharmaceutical pricing system may be approaching one of its most important structural shifts in […]

0